BioMark Diagnostics Inc. (CSE: BUX) has announced its participation in two life sciences conferences taking place in Quebec during the week of October 4, 2026, marking a dual public engagement for the liquid biopsy and metabolomics company. The company will attend the 16th Annual MSACL 2026 conference in Montreal and the inaugural BIOHorizon 2026 gathering in Laval, where its Chief Scientific Officer is scheduled to join a panel discussion. The appearances are positioned alongside ongoing expansion at BioMark's Quebec City medical laboratory, making the events potentially significant for investors tracking the company's path toward clinical deployment.

Key Points

  • BioMark Diagnostics Inc. (CSE: BUX | FSE: 20B | OTCQB: BMKDF) is a Vancouver-based liquid biopsy developer focused on early lung cancer detection through metabolomics.
  • The company will participate in MSACL 2026 (October 4–9, Montreal) and BIOHorizon 2026 (October 7–8, Laval) during the same week.
  • Chief Scientific Officer Dr. Jean-François Haince will join a BIOHorizon panel on October 8, 2026, addressing clinical translation of biomarker discoveries.
  • Investors may be watching for updates on laboratory certification progress and potential institutional partnerships arising from these engagements.

BioMark's Dual Quebec Conference Presence in October 2026

BioMark will attend MSACL 2026 at the Bonaventure Hotel Conference Centre in Montreal from October 4 to 9, 2026, participating in industry workshops alongside technology partners Sciex and Phytronix Technologies. The sessions will focus on clinical mass spectrometry workflows and assay applications. Separately, the company will attend the inaugural BIOHorizon 2026 event at the Sheraton Laval on October 7 and 8, 2026, a forum described in the release as connecting decision-makers, researchers, investors, and entrepreneurs across Quebec, Canada, and international markets.

CSO Panel Appearance Targets Clinical Translation of Biomarker Technology

Dr. Jean-François Haince, Chief Scientific Officer and General Manager, is scheduled to join the BIOHorizon panel discussion titled "Diagnostics: From Biomarker to Bedside" on October 8, 2026. According to the announcement, the discussion will address how biomarker discoveries are translated into functioning healthcare systems. The release quotes Dr. Haince stating that biomarkers generate value only when a laboratory can run them reliably, a clinician can interpret results, and a health system can reimburse them — framing the panel as directly relevant to BioMark's commercialisation strategy.

Quebec City Laboratory Expansion Underpins Conference Strategy

The announcement connects the conference appearances to active operational progress at BioMark's medical laboratory in Quebec City. The release states the facility is continuing to expand its analytical mass spectrometry capacity and validation protocols, advancing its portfolio of laboratory-developed tests toward certification and clinical deployment. President and CEO Rashid Bux is quoted in the release stating the company's objective is to translate its metabolomics platform advantage into expanded laboratory testing volume, institutional partnerships, and long-term commercial growth. The immediate share price impact was not clear from available public information.